27798-39-6

Basic information

• Product Name: 1-benzyl-3-broMobenzene
• Synonyms: 1-benzyl-3-broMobenzene;Benzene, 1-bromo-3-(phenylmethyl)-
• CAS NO: 27798-39-6
• Molecular Formula: C₁₃H₁₁Br
• Molecular Weight: 247.13044
• Mol File: 27798-39-6.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Refrigerator
• Solubility: Chloroform (Slightly), DMSO (Slightly), Ethyl Acetate (Slightly)
• CAS DataBase Reference: 1-benzyl-3-broMobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-benzyl-3-broMobenzene(27798-39-6)
• EPA Substance Registry System: 1-benzyl-3-broMobenzene(27798-39-6)

Safety Data

• Hazardous Substances Data: 27798-39-6(Hazardous Substances Data)

Usage

Uses

1-Benzyl-3-bromobenzene is used as a synthetic intermediate in the pharmaceutical industry for the development of various drugs.
Used in HIV-1 Integrase Inhibitors:
1-Benzyl-3-bromobenzene is used as a key intermediate in the synthesis of inhibitors targeting HIV-1 integrase, an enzyme essential for the replication of the HIV virus. These inhibitors play a crucial role in the development of antiretroviral drugs, which are vital in the treatment and management of HIV/AIDS.
Used in SGLT2 Inhibitors:
1-Benzyl-3-bromobenzene is also utilized in the preparation of C-arylglucoside inhibitors of the renal sodium-dependent glucose transporter SGLT2. SGLT2 inhibitors are a class of drugs used to treat type 2 diabetes by reducing glucose absorption in the body, thus helping to lower blood sugar levels. The compound's unique structure makes it a valuable building block in the development of these therapeutic agents.

Upstream product

• 1016-77-9 3-bromobenzophenone 
• 108-86-1 bromobenzene 
• 100-52-7 benzaldehyde 
• 108-36-1 1,3-dibromobenzene 
• 1711-09-7 3-bromobenzoyl chloride 
• 585-76-2 m-bromobenzoic acid 
• 3132-99-8 m-bromobenzoic aldehyde 
• 100-58-3 phenylmagnesium bromide 
• 15852-73-0 (3-Bromophenyl)methanol 
• 71-43-2 benzene 
• 16002-63-4 phenylmagnesium iodide 
• 591-17-3 meta-bromotoluene 
• 15961-35-0 4,4,6-trimethyl-2-phenyl-[1,3,2]dioxaborinane 
• 89598-96-9 (3-bromophenyl)boronic acid 

Downstream Products

• 143215-26-3 C₁₉⁽¹³⁾CH₁₆O 
• 74857-56-0 1-(3-benzylphenyl)ethan-1-one 
• 422550-74-1 (3-benzylphenyl){8-[(2-methoxyethoxy)-methoxy]-4-methylquinolin-7-yl }methanone 
• 1413302-21-2 C₁₉H₁₃N 
• 1016-77-9 3-bromobenzophenone 
• 13020-57-0 3-hydroxybenzophenone 
• 74167-91-2 ethyl2-(3-benzoylphenoxy)propanoate 
• 76981-46-9 2-(3-benzoylphenoxy)propanamide 
• 173394-24-6 (3-benzylphenyl)boronic acid 
• 1426943-25-0 3''-benzyl-2'-isobutyl-3-isopropyl[1,1':4',1'']terphenyl 
• 1413301-60-6 C₁₉H₁₇NO 
• 949909-68-6 C₁₉H₁₃NO₂ 
• 949909-69-7 C₁₉H₁₃N₅ 

Relevant articles and documents

Diflunisal Derivatives as Modulators of ACMS Decarboxylase Targeting the Tryptophan-Kynurenine Pathway

In the kynurenine pathway for tryptophan degradation, an unstable metabolic intermediate, α-amino-β-carboxymuconate-?-semialdehyde (ACMS), can nonenzymatically cyclize to form quinolinic acid, the precursor for de novo biosynthesis of nicotinamide adenine dinucleotide (NAD+). In a competing reaction, ACMS is decarboxylated by ACMS decarboxylase (ACMSD) for further metabolism and energy production. Therefore, the inhibition of ACMSD increases NAD+ levels. In this study, an Food and Drug Administration (FDA)-approved drug, diflunisal, was found to competitively inhibit ACMSD. The complex structure of ACMSD with diflunisal revealed a previously unknown ligand-binding mode and was consistent with the results of inhibition assays, as well as a structure-activity relationship (SAR) study. Moreover, two synthesized diflunisal derivatives showed half-maximal inhibitory concentration (IC50) values 1 order of magnitude better than diflunisal at 1.32 ± 0.07 μM (22) and 3.10 ± 0.11 μM (20), respectively. The results suggest that diflunisal derivatives have the potential to modulate NAD+ levels. The ligand-binding mode revealed here provides a new direction for developing inhibitors of ACMSD.

HETEROCYCLIC COMPOUND AND USE THEREOF

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I) : wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis treatment of narcolepsy.

Feedstocks to Pharmacophores: Cu-Catalyzed Oxidative Arylation of Inexpensive Alkylarenes Enabling Direct Access to Diarylalkanes

A Cu-catalyzed method has been identified for selective oxidative arylation of benzylic C-H bonds with arylboronic esters. The resulting 1,1-diarylalkanes are accessed directly from inexpensive alkylarenes containing primary and secondary benzylic C-H bonds, such as toluene or ethylbenzene. All catalyst components are commercially available at low cost, and the arylboronic esters are either commercially available or easily accessible from the commercially available boronic acids. The potential utility of these methods in medicinal chemistry applications is highlighted.

Spirocyclic derivatives

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease, disorder or condition ameliorated by inhibition of a dopamine transporter); and methods of treating patients with such compounds; wherein R1, R2, R3, R4, R5, R6, R9, R10, Q, X, Y, Z, A, L, B, m, n and p are as defined herein.

Rapid Wolff-Kishner reductions in a silicon carbide microreactor

Wolff-Kishner reductions are performed in a novel silicon carbide microreactor. Greatly reduced reaction times and safer operation are achieved, giving high yields without requiring a large excess of hydrazine. The corrosion resistance of silicon carbide avoids the problematic reactor compatibility issues that arise when Wolff-Kishner reductions are done in glass or stainless steel reactors. With only nitrogen gas and water as by-products, this opens the possibility of performing selective, large scale ketone reductions without the generation of hazardous waste streams.

Synthesis of structurally diverse diarylketones through the diarylmethyl sp3 C-H oxidation

Under open-flask conditions, an efficient method to assemble a series of diversely functionalized diarylketones in the presence of commercially available NBS has been developed. Yields of up to 99% have been achieved employing diarylmethanes as starting material. Based on 18O-labeled experiment, the addition of stoichiometric water eventually leads to excellent yields in all carbonylation cases.

A modular synthesis of teraryl-based α-helix mimetics, part 1: Synthesis of core fragments with two electronically differentiated leaving groups

Teraryl-based α-helix mimetics have proven to be useful compounds for the inhibition of protein-protein interactions (PPI). We have developed a modular and flexible approach for the synthesis of teraryl-based α-helix mimetics. Central to our strategy is the use of a benzene core unit featuring two leaving groups of differentiated reactivity in the Pd-catalyzed cross-coupling used for terphenyl assembly. With the halogen/diazonium route and the halogen/triflate route, two strategies have successfully been established. The synthesis of core building blocks with aliphatic (Ala, Val, Leu, Ile), aromatic (Phe), polar (Cys, Lys), hydrophilic (Ser, Gln), and acidic (Glu) amino acid side chains are reported. Turn on: Teraryl-based α-helix mimetics can be effectively produced by sequential Suzuki coupling of a central core fragment featuring electronically differentiated leaving groups with aryl boronic pinacol esters (see scheme; dppf=1,1′-bis(diphenylphosphino) ferrocene, DME=dimethoxyethane, Pin=pinacol, Tf=trifluoromethanesulfonyl). With a set of only 2×18 building blocks, all permutations of α-helix mimetics can be produced. Copyright

Substrate-Based fragment identification for the development of selective, nonpeptidic inhibitors of striatal-enriched protein tyrosine phosphatase

High levels of striatal-enriched protein tyrosine phosphatase (STEP) activity are observed in a number of neuropsychiatric disorders such as Alzheimer's disease. Overexpression of STEP results in the dephosphorylation and inactivation of many key neuronal

One-pot dual substitutions of bromobenzyl chloride, 2-chloromethyl-6- halogenoimidazo[1,2-a]pyridine and -[1,2-b]pyridazine by Suzuki-Miyaura cross-coupling reactions

A very simple, mild and inexpensive palladium-catalyzed cross-coupling of (hetero)arylboronic acids with benzylic halides occurs in good yield. This method was successfully expanded to two heterocyclic electrophiles and allowed onepot dual substitutions of bromobenzyl chloride, 2-chloromethyl-6- halogenoimidazo[1,2-a]pyridine or -[1,2-b]pyridazine, leading to numerous new unsymmetrical methylenelinked biaryl systems. Wiley-VCH Verlag GmbH & Co. KGaA, 2008.

Amino-imidazolones for the inhibition of beta-secretase

The present invention provides an amino-imidazolone compound of formula I Also provided are compositions and methods for the use thereof to inhibit β-secretase (BACE) and treat β-amyloid deposits and neurofibrillary tangles.